Philippines: Should your right to be healed be based on the location you live in?

The Philippines, a country where Medical Cannabis is strictly prohibited and where the punishment for Cannabis is more severe than being caught with hard drugs such as crystal meth, heroin, cocaine and the likes.

Several groups in the Philippines such as Porml, 420 Philippines, Internation Women’s Cannabis Coalition – Philippines (IWCC) just to name a few, are pushing for legalization of Medical cannabis to be granted to legitimate patients who suffer from debilitating disease such as epilepsy, cancer, multiple sclerosis, tumors, etc. The most active group is the Philippines Cannabis Compassion Society (PCCS) who leads the movement and is active in lobbying to pass the bill in Congress. PCCS work side by side with the author of the bill, Congressman Rodolfo Albano. PCCS also shares the stories of their patients to open the minds and hearts of the Congressmen to co-author the bill. The bill has 104 co-authors as of this writing and the bill needs to have at least 200 signatures to be endorsed by the Senate.

Some of the patients who have the financial capability to migrate to other countries or import Medical Cannabis from other countries where it is legal have significantly improved their health and some have been cured totally. However, the patients who are less fortunate are left to suffer and eventually die due to the fact that they cannot afford the cost of importation and/or migration to another country.

This migration not only happens in the Philippines, same scenarios happen in the United States of America (USA), as families move to a different state where Medical Cannabis is legal and to be able to use it to their patients, however, they are not allowed to bring it to a different state, forcing families to leave their family, friends and work behind.

As per the data released by Philippine Obstetrical and Gynecological Society in 2016, Philippines topped 197 countries with the most number of cases of breast cancer. It is also one of the countries worldwide with the highest prevalence rates of cancer.

183,000 people are affected by Epilepsy in the Philippines based on the data of the World Health Organization (WHO) in 2004 and the numbers just continue to keep on rising.

These data only proves that not only a few will benefit from Medical Cannabis but millions of Filipinos. It can improve the lives of millions suffering every single day and it can provide them a livable life. Once the bill has been enacted into a law everyone who is qualified to avail Medical Cannabis can do so with the guidance of the Department of Health (DOH), Philippines Drug Enforcement Agency (PDEA), and Dangerous Drug Board (DDB).


Write : By Anne Kristina Aguila

While Cannabis remains as a Schedule I Drug, Syndros, a form of synthetic THC received a Schedule II

While Cannabis is classified as a Schedule I Drug. Syndros (generic name: c-x dronabinol oral solution, a synthetic THC oral solution) manufactured by Insys Therapeutics, a Chandler, Arizona based pharmaceutical firm, receive the approval of Food and Drug Administration to be classified as Schedule II under the Controlled Substances Act, which would allow doctors to prescribe it.

Schedule II is the second-most restrictive drug classification category which is described as substances with a “high potential for abuse” but having some form of currently accepted medical use which includes Vicodin, cocaine, oxycodone, Adderall and Ritalin.

In 1985, FDA approved and regulated Marinol as a less-restrictive Schedule III substance. Marinol (dronabinol) is a man-made form of cannabis (also known as marijuana). Marinol is used to treat loss of appetite that causes weight loss in people with Acquired Immune Deficiency Syndrome (AIDS). Marinol is also used to treat severe nausea and vomiting caused by cancer chemotherapy. It is usually given after medicines to control nausea and vomiting have been tried without success.

According to GlobeNewswire, Syndros is a liquid formulation of the pharmaceutical cannabinoid dronabinol. Syndros is a new drug product indicated for use in chemotherapy patients to help alleviate their nausea and vomiting and AIDS patients with anorexia-associated weight loss, respectively,”

Saeed Motahari, President and Chief Executive Officer of INSYS, made a statement that “The launch of Syndros represents a pivotal milestone for us,”

“Syndros is the second product entirely developed and commercialized by INSYS. We are excited to make Syndros available to those patients in need and look forward to bringing additional novel therapeutic solutions to even more patients in the near future.”

Stephen Sherman, Senior Vice President, Regulatory Affairs of INSYS said, “Syndros is the first and only FDA-approved liquid dronabinol. It represents a viable alternative for the delivery of dronabinol and will fulfill a significant unmet need for both cancer patients undergoing chemotherapy who fail traditional antiemetics and AIDS patients who experience weight loss,”

According to The Cannabist, Health and Human Services officials said that liquid dronabinol has a higher potential for abuse than Marinol because the liquid formulation could be manipulated to produce extracts for vaping or edibles, according to the notice in the Federal Register.

Vetticaden told the Cannabist last year that chemically synthesized drugs are highly reliable and thus could meet the rigorous testing demands and standards from the FDA. A synthetic approach could mitigate any potency issues that patients could encounter when buying products from dispensaries.

Insys, has expressed concerns about “natural cannabis” in regulatory filings to the U.S. Securities and Exchange Commission, and the legalization of marijuana:

“Moreover, our cannabinoid products may compete with non-synthetic cannabinoid drugs, including therapies such as GW Pharmaceuticals’ Sativex and Epidiolex, especially in many countries outside of the United States where non-synthetic cannabinoids are legal. In addition, literature has been published arguing the benefits of natural cannabis, or marijuana, over dronabinol, and there are a number of states that have already enacted laws legalizing medicinal and recreational marijuana. There is some support in the United States for further legalization of marijuana. We also cannot assess the extent to which patients utilize marijuana illegally to alleviate (Chemotherapy-Induced Nausea and Vomiting), instead of using prescribed therapies such as approved dronabinol products.”

Last fall, Insys contributed $500,000 to the campaign against marijuana legalization in Arizona. The $500,000 donation from Insys Therapeutics, amounts to more than one-third of all money raised by Arizonans for Responsible Drug Policy, the group opposing legalization. According to campaign finance records maintained by, Insys is one of the largest single contributions to any anti-legalization campaign ever.

Insys is facing multiple complaints, investigations and lawsuits related to its Subsys fentanyl spray (under-the-tongue spray intended for cancer patients that contains fentanyl, a highly addictive and regulated synthetic opioid). It has been reported that Insys was accused of off-label marketing of the opioid painkiller and has faced allegations of providing kickbacks to doctors to prescribe it.

In a report by Reuters, Insys has been accused of paying doctors sham speaker fees in exchange for writing prescriptions of Subsys and of misleading insurers into believing patients who were prescribed the opioid had cancer when they actually did not.

Brnovich also sued three Arizona doctors, Steve Fanto, Nikesh Seth and Sheldon Gingerich, whom the lawsuit said Insys paid on average $200,000 while they wrote prescriptions that generated over $33 million in sales of Subsys from March 2012 to April 2017.

Brnovich said in a statement that, “We need to put a stop to the unethical and greedy behavior in the pharmaceutical industry that is fueling the opioid crisis in our state,”.

Insys is in talks with the U.S. Department of Justice to resolve the federal probe. Investigations are held by attorneys general in Oregon, New Hampshire and Illinois, Insys previously agreed to pay a combined $8.95 million to resolve any investigations.

The lawsuit seeks an injunction, restitution for customers and the disgorgement of any illegally gained profits.


Write By Anne Kristina Aguila

Israel: The Epicenter Of Medical Cannabis

Raphael Mechoulam | Hebrew University of Jerusalem (HUJI) | ResearchGateIsreal: The Grandfather of Medical Marijuana: Raphael Mechoulam, a professor, and researcher at Hebrew University, the man behind the discovery of tetrahydrocannabinol, commonly known as THC; the psychoactive compound in Cannabis. It all started in 1963 when Mechoulam secured 11 pounds of Lebanese hashish, which he used to identify, isolate and synthesize THC and study its medical use. He was also the first to decode the structure of CBD, the plant’s primary non-psychoactive ingredient. In 1992, Mechoulam and his team at Hebrew University in Jerusalem made a groundbreaking discovery on the physical reason why humans get high when using Cannabis, now known as the endocannabinoid system, and that the human brain produces its own cannabinoids – compounds that stimulate the body almost exactly the way THC does. “It turned out that the cannabinoids in the plant actually mimic the compounds that we form in our brain,” says Mechoulam.

Over the past 50 years, Israel conducts the world’s largest number of clinical trials testing the benefits of medicinal cannabis and has become a global destination for medical cannabis research and development. Israel was among the first countries to legalize the medicinal use and is one of just three countries with a government-supported medical cannabis program. On the other hand, recreational use remains illegal, however, the Israeli government has approved the export of medicinal cannabis products making it an offshore greenhouse for American cannabis companies seeking to overcome the federal roadblocks standing in their way.

While importing cannabis into the United States remains illegal under federal law, companies can still import from Israel by acquiring drug approval from the FDA by meeting the agency’s requirement for drug approval. The FDA has approved 3 drugs containing synthetic cannabinoids but it has never approved a product derived from botanical cannabis. According to the agency’s guidelines, “Study of marijuana in clinical trial settings is needed to assess the safety and effectiveness of marijuana for medical use.” Since initiating a clinical trial in the US is difficult, US companies resulted in partnering up with Israel’s pharmaceutical company to use their medical research facilities in Israel and conducting clinical trials there and applying for FDA approval of the botanical cannabis drug they are developing.

With one million square feet of cultivation fields, a 35,000-square-foot production plant, and 30,000 square feet of grow rooms and labs, Dr. Tamir Gedo’s company, Breath of Life Pharma (BOL), is about to open the world’s largest medical marijuana production, research, and development facility. According to Gedo’s estimates, BOL will produce 80 tons – more than 175,000 pounds – of cannabis per year.

Israel’s research on Cannabis has a great impact on the US cannabis industry, medical marijuana is now legal in 29 U.S. states and this is a direct result of Israeli research which made the study and research on Cannabis legitimate. Paul Armentano, deputy director of the D.C.-based National Organization for the Reform of Marijuana Laws (NORML) said. Without this research, “We wouldn’t have the scientific interest we have now around the world,”. He also added, “That really opened the door to making the study of cannabis and cannabinoids a legitimate avenue for more conventional scientists and researchers.”

Even if U.S. companies want to do a clinical trial on U.S. soil it is nearly impossible and time-consuming. In Israel, a cannabis clinical trial can get off the ground in a matter of months. “There’s a lengthy and arduous regulatory process for getting approval for doing studies, and limited resources at these agencies for processing those requests,” says Pollack, of Thomas Jefferson University. “It’s deliberately made very difficult for us.”

“I think they have approached the issue in a more even-handed and genuine way than the U.S. government has,” says Armentano of NORML. “There are onerous restrictions on conducting this research in the U.S. that don’t exist in Israel.”

“There’s a lengthy and arduous regulatory process for getting approval for doing studies, and limited resources at these agencies for processing those requests,” says Pollack, of Thomas Jefferson University. “It’s deliberately made very difficult for us.” In Israel, on the other hand, a cannabis clinical trial can get off the ground in a matter of months.

“I think they have approached the issue in a more even-handed and genuine way than the U.S. government has,” says Armentano of NORML. “There are onerous restrictions on conducting this research in the U.S. that don’t exist in Israel.”

Dr. Gedo is optimistic but, on the other hand, he is also realistic. He knows that the FDA will never get behind cannabis the plant as medicine, since it can’t be controlled as a consistent drug given that there are 140 active compounds in cannabis, and the composition of the flowers plucked from one branch can fluctuate wildly, by up to 300 percent and can’t have the same effect day in and day out.

“The experience of a user will vary a lot with the same strain,” says Gedo. “So even if you have the best-grown product, it will never become a scientific pharmaceutical product.”

Source :  By Anne Kristina Aguila

Medical Marijuana and Acute Pain Study

A new study is being conducted by Dr. Fenney out of Saint Francis Hospital and Medical center in Hartford Connecticut. The trial is state funded and will compare opioids and medical marijuana for treating acute pain, (ie a broken bone)

There are studies that suggest that medical marijuana is effective for chronic pain, which is pain that continues after an injury should have healed. Dr. Feeney wants to test marijuana for acute pain, where opioids have long been the drug of choice for physicians.
“The big focus from my standpoint is that this is an attempt to end the opioid epidemic,” he says. Overdoses from opioids, killed more than 30,000 people in 2015.
Schedule 1 Status

Marijuana is a Schedule I drug, which makes it very difficult for researchers to study. Scientists first have to apply for a license from the DEA, which can take years and the only available supply for researchers is the government’s marijuana grow facility at the University of Missipipi, which has limited supplies.

Feeney’s research on acute pain is able to get around the issues associated with marijuana’s scheduling. Medical marijuana is legal in the state of Connecticut. Instead of directly supplying the patients with marijuana, a doctor certifies a patient to use marijuana, and the patient then picks it up at a dispensary or pharmacy.

“The strains I have to select from are so pure and so potent that the stuff they get from the University of Mississippi pales in comparison,” says Feeney.
The trial includes 60 patients with rib injuries in total—30 on marijuana, 30 on opioids. Because of the study’s design, patients get to choose whether they use opioids and marijuana to control pain. So far, the hospitals have enrolled a quite a few patients. They’ve all chosen marijuana.

More Studies

Dan Clauw, who runs the pain lab at the University of Michigan, and his colleagues published a survey of patients who started using medical marijuana to alleviate pain. They cut their previous opioid use by two-thirds.

“They felt a lot better when their pain was being controlled by cannabis rather opioids because opioids have a lot of side effects,” he says. “Those side effects include dizziness, constipation, sexual dysfunction and—in the case of overdoses—breathing problems. That’s because opioids receptors are also in the brainstem, the part of the brain that regulates breathing. Marijuana acts on a different set of receptors.”

Source: Medical Marijuana 411.

New potent derivative of cannabidiol could be key in the development of more effective cannabis-based medicine

A considerable number of human and animal studies indicate that Cannabidiol (CBD) exerts therapeutic effects in a wide range of health disorders. These include anxiety disorders, neuropathic pain, epilepsy, cancer treatment-related symptoms, and possibly schizophrenia, psychosis, depression and obsessive compulsive disorder.

Considering CBD’s general safety, it is somewhat surprising that it has not yet been marketed as a stand-alone drug (Sativex, which is available in Canada and some European countries, contains a 1:1 ration of THC and CBD). A reason for this might be due to its low potency, which requires that large doses be administered to achieve significant therapeutic effects. For instance, in human studies of anxiety, doses of 300 to 600 mg of CBD are needed to achieve effects comparable to those of 10 mg of diazepam (source).

In an attempt to overcome this hurdle, an international team of researchers from Israel and Brazil has been trying to create more potent molecules derived from CBD. The team focused on fluorination, a method employed by pharmacists worldwide to enhance endogenous and synthetic drugs, which is applied in nearly 20% of the new drugs released in the market. Using this method to add a fluorine atom to the “aromatic ring” of the CBD molecule, the researchers obtained a new and much more potent molecule (HUF-101). Their successful finding was published this July in the journal PLOS ONE.

After the chemical synthesis of HUF-101, different concentrations of the compound were tested in mice under four behavioral assays. These testrd for the presence of any protective effects against anxiety, depression, schizophrenia and compulsive behavior.

Overall, the experiment revealed strong protective effects of HUF-101 in the four assays. More importantly, when the data were compared to previous studies, it was obvious that similar effects to those of CBD were being achieved at much lower concentrations of HUF-101. In the anxiety and depression tests, comparable effects were observed at a tenth of the concentration; while in the schizophrenia and compulsive behavior tests, concentrations ranging from a twentieth to a third were holding the same effects.

In a subsequent manipulation, the researchers found that when they blocked CB1 or CB2 receptors, both CBD and the derivative HUF-101 lost their efficacy in preventing compulsive behavior. This suggests that an indirect activation of these receptors by both drugs was likely mediating the behavioral effect. The authors did not attempt to test what mechanisms were responsible for the remaining behaviors due to logistical limitations. Considering the many mechanisms of action known for CBD and the fact that none is likely to singlehandedly explain all the effects observed, such an endeavor would have been prohibitively long.

Several other issues remain to be tackled in future research, including the tracing of HUF-101 toxicity profile in different animal models, the study of its pharmacodynamic parameters, and assessing how well these effects generalize to other types of assays that measure similar aspects of behavior. Only after addressing these issues will any prospects of clinical human trials be feasible. For now, this new compound remains an interesting scientific finding with potential applications in the development of more effective cannabis-based medicines.

Source : New Lift

44 medical studies that demonstrate cannabis can treat cancer

Declared war on drugs in the early 1970’s one of the not-so-obvious results of this mammoth policy shift was that scientific researchers were set back decades in discovering new cannabinoid-based treatments for serious medical conditions. In just a few decades the U.S. government was able to wipe thousands of years of anecdotal as well as solid scientific evidence of the efficacy of cannabis in treating a wide range of ailments and diseases from our collective medical knowledge.

For those who have spent a considerable amount of time fighting for cannabis law reform it comes as no surprise, then, that our government and pharmaceutical corporations have long fought to keep secret the fact that cannabis can be an effective treatment for certain types of cancer. And we’re not just talking about relieving nausea that comes from chemotherapy and radiation treatment, but actually shrinking or eliminating cancerous tumors.

Brain Cancer

Mouth and Throat Cancer

Breast Cancer
Lung Cancer
Uterine, Testicular, and Pancreatic Cancers
Prostate Cancer

Colorectal Cancer

Ovarian Cancer
Blood Cancer
Skin Cancer
Liver Cancer
Biliary Tract Cancer
Bladder Cancer
Other Cancers

Source : Southern Cannabis

New Cannabis Pill May Replace Traditional Painkillers

A company has created the first ever cannabis pill designed to relieve menstrual cramp pain in women.

FORIA Relief has been carefully crafted using a delivery system intended to maximize the muscle relaxing and pain relieving properties of cannabis without inducing a psychotropic “high.” Cannabis has a long, cross-cultural history of use as a natural aid in easing symptoms associated with menstruation. Our intention is to share the powerful medicinal properties of this plant while utilizing modern extraction techniques to standardize purity and potency, thereby ensuring a safe and accessible experience for all women.
The active ingredients are extracted from pesticide-free cannabis flowers and made into exact doses—60 mg of tetrahydrocannabinol (THC) and 10 mg of cannabidiol (CBD)—in a microbial-free process. As the manufacturer states, it does not make you high.

Foria Relief contains both THC and CBD, the two key active cannabinoid compounds found in cannabis. Together they activate certain cannabinoid receptors in the pelvic region when introduced into the body via these specially formulated suppositories. Users have reported a significant decrease in the pain and discomfort often associated with menstruation. The cannabinoids directly impact the immune system and the nerve endings of the uterus, cervix, ovaries and surrounding smooth muscle tissues. THC positively affects the nerves and assists in blocking out pain while also allowing for more pleasant signals to be received by the brain. CBD works in the immune system by suppressing the mechanisms responsible for inflammation. CBD also slows down electrical signaling to muscles and allows them to relax, thereby reducing cramping.

Since the pelvic region has more cannabinoid receptors than anywhere else in the body, this product is a logical move. We have reported on many studies discovering the amazing benefits of cannabis as medicine, centered on its use to stimulate our body’s endocannabinoid systems.

All of the muscles that had been cramped and clenched so tight gradually released and my body relaxed. Where I had been painfully aware of every inch of my midsection, suddenly it felt as though I had no midsection at all. From my waist down to my thighs, it was almost as if my groin had simply dissolved and was floating in some galaxy far, far away.

The Food and Drug Administration has not yet approved this product as a treatment, but that isn’t stopping people from trying it and finding that it works. Foria Relief is only available in California now, although hopefully this will expand as cannabis legalization is spreading rapidly.

The Importance of Enhancing Your Endocannabinoid System

Cannabis extracts are proving to be remarkably effective against a wide range of diseases for thousands of people. Unfortunately, there is a subset of the population that responds negatively or not at all. Numerous factors influence an individual’s unique response to cannabis medicine, including genetics. Some people may never be able to benefit from cannabis due to rare genetic mutations. However, a major cause of poor experiences may be controllable – the health of the endocannabinoid system.

Cannabis and the Endocannabinoid System
Cannabis is effective because it works through the endocannabinoid system, the function of which is to maintain homeostasis. Given this role, it may often be the best place to target for treating disease, which fundamentally is a state of non-homeostasis. For cannabis to work most effectively, the endocannabinoid system needs to be healthy.
While concentrated cannabis can directly improve endocannabinoid signaling, they are not a cure-all. Other restorative and enhancement techniques must be utilized as well. If the endocannabinoid system can be enhanced before or alongside cannabis extract therapy, the healing results are almost certain to improve considerably.
Enhancing Your Endocannabinoid System
There are two primary ways to strengthen your endocannabinoid system. The first is by avoiding stimuli that deplete endocannabinoid resources. For example, one of the functions the system mediates is the reduction of inflammation. Therefore, eating inflammatory foods like refined grains, sugar, and trans fats can eventually be overwhelming. Stress also recruits endocannabinoid resources, so poor nutrition combined with stress can be especially damaging. Eating an anti-inflammatory diet rich in fruits, vegetables, nuts, seeds, and healthy fat sources like olive oil, fish, and eggs is very helpful, as is engaging in stress-reducing activities like meditation and yoga.
The second pathway to empowerment is consuming things that up-regulate endocannabinoids or cannabinoid receptors. For example, probiotics increase CB2 receptors in intestinal cells and may even potentially reduce pain by acting through those receptors. Exercising, including running and biking, increases endocannabinoid levels. Olive oil, in addition to being anti-inflammatory, may help fight colon cancer by increasing CB1 receptors on the cancer cells.

Source: Medical Jane

These 5 popular prescription drugs could be replaced with medicinal marijuana

That pharmaceutical drugs are labeled “popular” belies a tragic commentary on the success of death merchants promoting their womb to tomb toxic concoctions. These sample poisons arrive on the shelves via targeted media and promotional campaigns, aided by a well-oiled pipeline of white washed sepulchers posing as physicians. But here’s the good news: a national trend of recognizing and delivering the healing powers of herbs is underway. Move over Big Pharma, because some of your death inducing pharmaceuticals can be replaced by medical marijuana for many patients who suffer from conditions like chronic pain, anxiety, ADHD, insomnia and depression.

The list of five begins with Vicodin, a highly prescribed pain medication. While not a pure narcotic like Oxycontin, Vicodin does have an opioid component called hydrocodone mixed with acetaminophen, or Tylenol. Misuse of any narcotic can lead to death. In fact, according to The Week, the Purdue pushers of Oxycontin have been blamed for single handedlycreating an opiate addicted culture in the U.S. and was fined over $600 million for that offense:

“In 2007, in United States of America v. The Purdue Frederick Company, Inc., Purdue and its top executives pleaded guilty to charges that it misled doctors and patients about the addictive properties of OxyContin and misbranded the product as ‘abuse resistant.’ Prosecutors found a ‘corporate culture that allowed this product to be misbranded with the intent to defraud and mislead.’ Purdue Pharma paid $600 million in fines, among the largest settlements in U.S. history for a pharmaceutical company.”

Medical marijuana of all strains, types, and delivery methods, including cannabidiol, or CDB oil, never killed anyone. On the contrary, it has saved lives.

And then there’s Xanax, the number one prescribed psychiatric medication in the United States. Xanax is a benzodiazpam and can be extremely addictive and dangerous. Certain strains of medical marijuana may help lessen panic and anxiety, as reported in ATTN:

“Humans have natural endocannabinoid systems that regulates anxiety, and when certain cannabinoids are introduced to the body, they have been shown to significantly reduce anxiety.”

Another area where medical marijuana can replace the pharmaceutical’s market share is for those individuals who have been prescribed Adderall, a stimulant used to combat what is commonly called Attention Deficit Disorder. One wonders if this relatively new scourge is created by the technological onslaught of digital media forced into our children’s brains and eyeballs, combined with our disconnectedness with nature and the relentless competition of the times and season we live in. College students have been known to feign ADHD symptoms in want of some stimulant to pull off all night study sessions. Whether created, real or contrived, no one knows the end game of Adderall and Ritalin. Seems that certain strains of medical marijuana would be a much more prudent choice.

Fourth on the list of pharmaceuticals that could be replaced by medical marijuana is Ambien, a sleep aid used for insomnia. Data compiled by Leaf Science states:

“… chemicals in marijuana, known as cannabinoids, actually mimic the activity of chemicals naturally found in the brain. These biological pathways make up the body’s endocannabinoid system, which is responsible for sleep, among other things.”

Other benefits of medical marijuana for sleep disorders include falling asleep faster, sleeping more deeply and experiencing better breathing, which is critically important for apnea disorders.

Number five on the list of pharmaceuticals getting the brush off for a medical marijuana alternative is the antidepressant Zoloft. The long list of dangers of antidepressants created with SSRIs, or serotonin reuptake inhibitors, include birth defects, suicide and homicide. It’s abundantly clear that the amazing marijuana herb, originally given to man in the garden is a far more appropriate way to handle these issues, yes?

In conclusion, let’s review one line from Hippocratic Oath, written in 400 B.C., courtesy of the Internet Classics Archive:“I will give no deadly medicine to any one if asked, nor suggest any such counsel; and in like manner I will not give to a woman a pessary to produce abortion…”

Let’s get back to life and health. Let’s get back to the garden. Let’s get back to the herb. We were created for it, and it was crafted especially for us.

Source : Home Health Care

Fibromyalgia: Is Cannabis The Best Treatment?

Prescription drugs when it comes to fibromyalgia relief. This phenomenon isn’t surprising; researchers have been pushing for cannabis-based therapies for the disease for over the past 12 years. Luckily, there are now more options than ever for patients hoping to kick narcotics and find relief in a more natural and effective way.

What Is Fibromyalgia?
For decades, fibromyalgia (FM) patients have gotten the run-around from the medical community. Ten years ago, medical professionals were still arguing over whether or not fibromyalgia actually exists. Fortunately, most of them have now come to their senses. Also known as myofascial pain syndrome, the precise cause of fibromyalgia has yet to be found.

While the primary trait is seemingly unexplained and often debilitating pain, the illness actually comes with a wide variety of symptoms that range from:

Chronic pain with specific tender points
Widespread stiffness in the muscles
Sleep Disturbances
Irritable Bowl Syndrom (IBS)
Depression and Low Mood
The Endocannabinoid System and Fibromyalgia

There’s something interesting about the series of symptoms listed above. These are the exact same symptoms that doctors like Ethan Russo have discussed time and time again in endocannabinoid research. Dr. Ethan Russo is a neurologist and pharmacologist. He is currently the Medical Director of Phytecs, a company that develops medicines, cosmetics, and lifestyle products that incorporate cannabinoid medicines. Cannabinoids are compounds found in the marijuana plant that take the place of endocannabinoids in our bodies.

In the early 2000s, Russo suggested that fibromyalgia may actually be a part of a larger disease called Clinical Endocannabinoid Deficiency (CECD). You can think of the endocannabinoid system (ECS) as a giant communication network in your body. Different chemicals known as “endocannabinoids” attach to receptors on your cells, telling them what to do. The ECS links certain parts of your brain to corresponding body parts, so a disruption or chemical imbalance in the endocannabinoid system means that these communication signals get disrupted.

The result can be an array of symptoms, including:

Mood issues
Sleep problems
Gastrointestinal issues
Muscle spasticity
Here’s a brief summary of research suggesting that the endocannabinoid system may play a part in fibromyalgia:

Study 1: Is CECD A Thing?

Russo first proposed the concept of CECD in 2003. In his paper, he links IBS, migraine, and fibromyalgia. He concludes that these conditions “display common clinical, biochemical and pathophysiological patterns that suggest an underlying clinical endocannabinoid deficiency that may be suitably treated with cannabinoid medicines”.

Study 2: An Argument For Cannabinoid Medicine
In 2008, Russo expanded on his original CEDC paper and focused specifically on pain. In this article, he explained that THC reduces the hypersensitivity to pain experienced by both migraine and fibromyalgia patients. THC fills in for our own body’s natural endocannabinoid, anandamide. This is again, strong evidence linking these diseases to the endocannabinoid system.

He argues further that cannabinoid medicines have other side benefits, including anti-nausea, anti-insomnia, and neuroprotective antioxidant properties. These additional benefits may help relieve some of the other symptoms often experienced by fibromyalgia patients.

Study 3: Cannabinoids Improve Wellbeing

Researchers from the University of Manitoba treated fibromyalgia patients with Nabilone, a synthetic cannabinoid. Researchers found that the cannabinoid was well-tolerated and decreased pain. At the 4-week mark in the study, patients saw drastic decreases in tender points and anxiety symptoms. They also saw significant improvements in results from Fibromyalgia Impact Questionnaires (FIQ). The FIQ tests for quality of life disturbances like depression, fatigue, interference with work, muscle stiffness, and overall physical functioning.

“This suggests that nabilone is an effective treatment even for those with severe cases of fibromyalgia with marked functional impairment,” write the study authors.

Study 4: CECD Revisited
Ten years after Russo’s first CECD was published, California-based researchers revisited his initial discussion. In their literature review, they confirmed evidence that imbalances in the endocannabinoid system play a role in fibromyalgia, IBS, and chronic migraine. They also suggested that ECS deficiencies may play a key role in a host of other diverse neurological and otherwise seemingly unexplained illnesses.

How Can Cannabis Help?

The list above is only the beginning when it comes to understanding the precise connection between fibromyalgia and the ECS. Only clinical trials and more research will be able to say for sure just how effective cannabis-based medicines can be in treating this illness. In the meantime, there are a few significant ways marijuana can help relieve symptoms:

Sleep disturbances are all-too-common for fibromyalgia patients. In fact, some researchers claim that sleep disturbances coupled with tender points are the defining characteristics of the illness. Marijuana not only can help you fall asleep, but night-time medication extends your deep sleep cycle. Getting a good nights’ rest is extremely important for fibromyalgia patients, as too many interruptions increases your likelihood of pain flare-ups the next day.

To ensure that you actually get some sleep, make sure you’re smoking/vaping/eating a heavy indica strain.

Aim for strains like:

Afghan Kush
Grandaddy Purple
Northern Lights
Via an online survey by the National Pain Foundation and, 62% of cannabis-consuming fibromyalgia patients found the herb “very effective” in relieving pain. This is actually quite amazing because marijuana drastically outperformed common prescription drugs like Cymbalta, Lyrica, and Savella. Only 8-10% of patients reported that these drugs were “very effective” in controlling symptoms.

This isn’t the only research that’s shown marijuana is a powerful painkiller. Several studies have shown that cannabis can either work in tandem with opiates or replace them altogether.

Aim for strains like:

Sour Diesel
Purple Trainwreck
Fun fact: you have cannabinoid receptors in your skin. So, cannabis topicals might be a good addition to ingested or inhaled marijuana. You can gently rub marijuana-infused lotions, balms, or oils onto tender points for additional pain relief.

Muscle Spasticity

Muscle spasms, tightness, and twitching are not uncommon in FM patients. Underneath each trigger point lies a contracted muscle. These trigger points can differ pain to different parts of the body when pressed. Muscle spasms and twitching can also happen a lot at night, interrupting sleep. Fortunately, cannabis can help.

Marijuana’s ability to put an end to muscle spasms came to light via research on Multiple Sclerosis (MS). In a 2011 study, mice injected with a mock form of MS. The injection caused extreme muscle tightness, contractions, and spasticity. After receiving CBD injections, the mice regained mobility and saw a drastic improvement in symptoms. CBD is a non-psychoactive cannabinoid.

There is even a marijuana-derived prescription drug out on the market in many countries. The drug, Sativex, contains a 1:1 ratio of THC to CBD. While muscle spasms from fibromyalgia may be different from those in MS patients, cannabis can still work wonders on any muscle that seems to have developed a mind of its own.

Aim for strains like:

One to One
White Berry
Having any chronic illness is never easy, but feeling constantly fatigued and in pain without explanation can be very taxing. Enjoying a little cannabis is a sure-fire way to put your mind at ease and even a smile on your face. In low doses, psychoactive THC is a potent antidepressant. Other non-psychoactive cannabinoids like CBD and CBC also have strong mood-lifting properties.

Source : Health Care Plane